FDA supplemental approval: Oxycodone Hydrochloride (REMS)

AI Summary

This is an FDA supplemental approval (dated 2026-06-18) of a REMS program for oxycodone hydrochloride tablets (5 mg, 15 mg, and 30 mg) submitted by Actavis Elizabeth. The record documents the regulatory action itself but contains no clinical trial data, efficacy outcomes, safety comparisons, or study populations.

Plain-language summary

This is an FDA supplemental approval action for a Risk Evaluation and Mitigation Strategy (REMS) requirement for oxycodone hydrochloride tablets; it is a regulatory record, not a clinical trial, and does not report efficacy or safety outcome data.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory record documents an approved REMS requirement for oxycodone hydrochloride tablets but does not provide clinical evidence or trial outcome data to inform prescribing decisions. Clinicians should consult the approved REMS program requirements and the full product labeling.

Caveats

• This record does not contain clinical trial results, efficacy data, safety comparisons, or adverse event outcomes.
• No study population, sample size, or comparative analysis is reported.
• The specific requirements of the REMS program are not detailed in this regulatory record.
• No information on the clinical rationale or supporting evidence for the REMS approval is provided.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.